

**Editor**

Tore K Kvien

Associate Editors

Francis Berenbaum
Hans Bijlsma
David Pisetsky
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 10.377

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2016 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission ARD is published by BMJ Publishing Group Ltd typeset by Nova Techset Private Limited, Bengaluru & Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431 POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.



Receive regular table of contents by email.
Register using this QR code.

Editorials

947 Separately tackling the development of erosions with denosumab: ultimately closing a gap in the treatment of patients with rheumatoid arthritis or trying too hard too late?
P Verschueren, R Westhovens

950 Flare in axial spondyloarthritis. The dark side of the outcome
D Wendling, C Prati

Viewpoint

952 Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force
C Strehl, J W J Bijlsma, M de Wit, M Boers, N Caeyers, M Cutolo, B Dasgupta, W G Dixon, R Geenen, T W J Huizinga, A Kent, A L de Thurah, J Listing, X Mariette, D W Ray, H U Scherer, R Seror, C M Spies, S Tarp, D Wiek, K L Winthrop, F Buttgerit

Criteria

958 Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD
I Koné-Paut, F Shahram, M Darce-Bello, L Cantarini, R Cimaz, M Gattorno, J Anton, M Hofer, B Chkirate, K Bouayed, I Tugal-Tuteku, J Kuemmerle-Deschner, H Agostini, S Federici, A Arnoux, C Piedvache, S Ozen, the PEDBD group

Recommendation

965 Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative
A Baillet, L Gossec, L Carmona, Maarten de Wit, Y van Eijck-Hustings, H Bertheussen, K Alison, M Toft, M Kouloumas, R J O Ferreira, S Oliver, A Rubbert-Roth, S van Assen, W G Dixon, A Finckh, A Zink, J Kremer, T K Kvien, M Nurmohamed, D van der Heijde, M Dougados

Review

974 The changing landscape of biosimilars in rheumatology
T Dörner, V Strand, P Comes, J Gonçalves, L Gulácsy, J Kay, T K Kvien, J Smolen, Y Tanaka, G R Burmester

Clinical and epidemiological research

983 Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with Rheumatoid arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
T Takeuchi, Y Tanaka, N Ishiguro, H Yamanaka, T Yoneda, T Ohira, N Okubo, H K Genant, D van der Heijde

991 Preliminary definitions of 'flare' in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative
L Gossec, A Portier, R Landewé, A Etcheto, V Navarro-Compán, F Kroon, D van der Heijde, M Dougados

997 Occupational exposure to textile dust increases the risk of rheumatoid arthritis: results from a Malaysian population-based case-control study
C L Too, N A Muhamad, A Ilar, L Padyukov, L Alfredsson, L Klareskog, S Murad, C Bengtsson, MyEIRA Study Group

1003 The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis
G S Hazlewood, J C Thorne, J E Pope, D Lin, D Tin, G Boire, B Haraoui, C A Hitchon, E C Keystone, S Jamal, V P Bykerk, for the CATCH Investigators

1009 Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study
E Hachulla, P-Y Havron, P Carpentier, C Agard, E Chatelus, P Jeco, L Mouthon, V Queyrel, A-L Fauchais, U Michon-Pasturel, R Jaussaud, A Mathian, B Granel, E Diot, D Farge-Bancel, A Mekinian, J Avouac, H Desmurs-Clavel, P Cleron, on behalf of the SEDUCE study group

1016 Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study
A Molit, A Etcheto, D van der Heijde, R Landewé, F van den Bosch, W B Molano, R Burgos-Vargas, P P Cheung, E Collantes-Estevez, A Decdhar, B El-Zorkany, S Erdes, J Gu, N Hajjaj-Hassoumi, U Kiltz, T-H Kim, M Kishimoto, S-F Luo, P M Machado, W P Maksymowych, J Maldonado-Cocco, H Marzo-Ortega, C-M Montecucco, S Ozgocmen, F van Gaalen, M Dougados

1024 Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naïve, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques
P G Conaghan, M Ostergaard, M A Bowes, C Wu, T Fuerst, D van der Heijde, F Irazoque-Palazuelos, O Soto-Raices, P Hrycaj, Z Xie, R Zhang, B T Wyman, J D Bradley, K Soma, B Wilkinson

1034 Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis
A Sepriano, R Landewé, D van der Heijde, J Sieper, N Akkoc, J Brandt, J Braun, E Collantes-Estevez, M Dougados, O Fitzgerald, F Huang, J Gu, Y Kirazli, W P Maksymowych, H Marzo-Ortega, I Olivieri, S Ozgocmen, E Roussou, S Scarpatto, I J Sorensen, R Valle-Oñate, F Van den Bosch, I van der Horst-Bruinsma, U Weber, J Wei, M Rudwaleit, on behalf of ASAS

MORE CONTENTS ►

COPE

Member since 2008

JMD0008

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>

equator
network

recycle
When you have finished
with this please recycle it

MCQs

The online version of this article contains multiple choice questions hosted on BMJ Learning.

- 1043** Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial
J Dale, A Stirling, R Zhang, D Purves, J Foley, M Sambrook, P G Conaghan, D van der Heijde, A McConnachie, I B McInnes, D Porter
- 1051** Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF)
E Demirkaya, C Acikel, P Hashkes, M Gattomo, A Gul, H Ozdogan, T Turker, O Karadag, A Livneh, E Ben-Chetrit, S Ozen, FMF Arthritis Vasculitis and Orphan disease Research in pediatric rheumatology (FAVOR)
- 1057** Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
T Takeuchi, Y Tanaka, M Iwasaki, H Ishikura, S Saeki, Y Kaneo
- 1065** Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
C J Edwards, F J Blanco, J Crowley, C A Birbara, J Jaworski, J Aelion, R M Stevens, A Vessey, X Zhan, P Bird
- 1074** Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol
F Perez-Ruiz, J S Sundry, J N Mimer, M Cravets, C Storgard, for the RDEA594-203 Study Group
- 1081** Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
G R Burmester, W F Rigby, R F van Vollenhoven, J Kay, A Rubbert-Roth, A Kelman, S Dimonaco, N Mitchell
- 1092** The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort
J Guzman, K Oen, A M Huber, K W Duffy, G Boire, N Schiff, R A Berard, D M Levy, E Stringer, R Scuccimarrì, K Morishita, N Johnson, D A Cabral, A M Rosenberg, M Larché, P Dancy, R E Petty, R M Laxer, E Silverman, P Miettunen, A-L Chetaille, E Haddad, K Houghton, L Spiegel, S E Turvey, H Schmeling, B Lang, J Ellsworth, S E Ramsey, A Bruns, J Roth, S Campillo, S Benseler, G Chédeville, R Schneider, S M L Tse, R Bolaria, K Cross, B Feldman, D Feldman, B Cameron, R Jurecák, J Dorval, C LeBlanc, C St. Cyr, M Gibbon, R S M Yeung, C M Duffy, L B Tucker, for the ReACCh-Out investigators
- 1099** Identification of novel acetylated vimentin antibodies in patients with early inflammatory arthritis
M Juarez, H Bang, F Hammar, U Reimer, B Dyke, I Sahbudin, C D Buckley, B Fisher, A Filer, K Raza
- 1108** Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orenzia and Rheumatoid Arthritis (ORA) registry
J H Salmon, J E Gottenberg, P Ravaud, A Cantagrel, B Combe, R M Flipo, T Schaeverbeke, E Hovenagel, P Gaudin, D Loeuille, S Rist, M Dougados, J Sibilia, X Le Loët, O Meyer, E Solau-Gervais, C Marcelli, T Bardin, I Pane, G Baron, E Perrodeau, X Mariette, on behalf of all the investigators of the ORA registry and the French Society of Rheumatology
- 1114** Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis
J F Baker, P G Conaghan, P Emery, D G Baker, M Ostergaard
- 1120** Does a family history of RA influence the clinical presentation and treatment response in RA?
T Frisell, S Saevarsdottir, J Askling
- 1126** Effects of needs-based patient education on self-efficacy and health outcomes in people with rheumatoid arthritis: a multicentre, single blind, randomised controlled trial
M Ndosi, D Johnson, T Young, B Hardware, J Hill, C Hale, J Maxwell, E Roussou, A Adebajo
- 1133** Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
K L Winthrop, S-H Park, A Gul, M H Cardiel, J J Gomez-Reino, Y Tanaka, K Kwock, T Lukic, E Mortensen, D Ponce de Leon, R Riese, H Valdez
- 1139** Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register
J H Humphreys, M K Verheul, A Barton, A J MacGregor, M Lunt, R E M Toes, D P M Symmons, L A Trouw, S M M Verstappen
- 1145** PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome
D F Fiorentino, M Presby, A N Baer, M Petri, K E Rieger, M Soloski, A Rosen, A L Mammen, L Christopher-Stine, L Casciola-Rosen
- 1152** Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials
R Wang, A Dasgupta, M M Ward
- 1161** Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system
P M Izmirly, A Saxena, S K Sahl, U Shah, D M Friedman, M Y Kim, J P Buyon
- 1166** Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type
S Unizony, M Villarreal, E M Miloslavsky, N Lu, P A Merkel, R Spiera, P Seo, C A Langford, G S Hoffman, C G M Kallenberg, E William St. Clair, D Ikle, N K Tchao, L Ding, P Brunetta, H K Choi, P A Monach, F Fervenza, J H Sione, U Specks, for the RAVE-ITN Research Group

Basic and translational research

- 1170** Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis
P F Kerkman, E Fabre, E I H van der Voort, A Zaldumbide, Y Rombouts, T Rispen, G Wolbink, R C Hoeben, H Spits, D L P Baeten, T W J Huizinga, R E M Toes, H U Scherer
- 1177** Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis
M Corbera-Bellalta, E Planas-Rigol, E Lozano, N Terrades-García, M A Alba, S Prieto-González, A García-Martínez, R Albero, A Enjuanes, G Espigol-Frigolé, J Hernández-Rodríguez, P Roux-Lombard, W G Ferlin, J-M Dayer, M H Kosco-Vilbois, M C Cid
- 1187** RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation
L Danes, N Komatsu, M M Guerrini, S Sawa, M Armaka, G Kollias, T Nakashima, H Takayanagi

- 1196** DNA methylation analysis of the temporal artery microenvironment in giant cell arteritis
P Coit, L B De Loti, B Nan, V M Elner, A H Sawalha
- 1203** Inactivation of autophagy ameliorates glucocorticoid-induced and ovariectomy-induced bone loss
N-Y Lin, C-W Chen, R Kagwiria, R Liang, C Beyer, A Distler, J Luther, K Engelke, G Schett, J HW Distler
- 1211** Deficiency of sorting nexin 10 prevents bone erosion in collagen-induced mouse arthritis through promoting NFATc1 degradation
C Zhou, Y You, W Shen, Y-Z Zhu, J Peng, H-T Feng, Y Wang, D Li, W-W Shao, C-X Li, W-Z Li, J Xu, X Shen
- 1219** Alpha-1-anti-trypsin-Fc fusion protein ameliorates gouty arthritis by reducing release and extracellular processing of IL-1 β and by the induction of endogenous IL-1Ra
L A B Joosten, T O Crişan, T Azam, M C P Cleophas, M I Koenders, F L van de Veerdonk, M G Netea, S Kim, C A Dinarello
- 1228** Agrin mediates chondrocyte homeostasis and requires both LRP4 and α -dystroglycan to enhance cartilage formation in vitro and in vivo
S Eldridge, G Nalesso, H Ismail, K Vicente-Greco, P Kabouridis, M Ramachandran, A Niemeier, J Herz, C Pitzalis, M Perretti, F Dell'Accio
- 1236** Neutrophil microvesicles resolve gout by inhibiting C5a-mediated priming of the inflammasome
A Cumpelik, B Ankele, D Zecher, J A Schifferli
- 1246** Blocking the tropomyosin receptor kinase A (TrkA) receptor inhibits pain behaviour in two rat models of osteoarthritis
L N Nwosu, P I Mapp, V Chapman, D A Walsh
- 1255** Crystal structure of *Porphyromonas gingivalis* peptidylarginine deiminase: implications for autoimmunity in rheumatoid arthritis
A B Montgomery, J Kopec, L Shrestha, M-L Thezenas, N A Burgess-Brown, R Fischer, W W Yue, P J Venables

Letters

- 1262** Five-year follow-up of radiographic sacroiliitis: progression as well as improvement?
A Sepriano, M Rudwaleit, J Sieper, R van den Berg, R Landewé, D van der Heijde
- 1263** Reliability of the quantitative assessment of peripheral blood perfusion by laser speckle contrast analysis in a systemic sclerosis cohort
V Lambrecht, M Cutolo, F De Keyser, S Decuman, B Ruaro, A Sulli, E Deschepper, V Smith

Correction

- 1254** Correction

Electronic pages

Correspondence

- e31** Towards standardisation of histopathological assessments of germinal centres and lymphoid structures in primary Sjögren's syndrome
M R Hillen, F Barone, T R D J Radstake, J A G van Roon
- e32** Need for consensus guidelines to standardise the assessment of germinal centres and other histopathological parameters in salivary gland tissue of patients with primary Sjögren's syndrome
K Delli, E A Haacke, S Ihrler, B van der Veet, A Vissink, H Bootsma, F K L Spijkervet, F G M Kroese
- e33** Do high numbers of salivary gland-infiltrating B cells predict better or worse outcomes after rituximab in patients with primary Sjögren's syndrome?
D Cornec, S Costa, V Devauchelle-Pensec, L Chiche, A Saraux, J-O Pers
- e34** In primary Sjögren's syndrome high absolute numbers and proportions of B cells in parotid glands predict responsiveness to rituximab as defined by ESSDAI, but not by SSRI
K Delli, E A Haacke, F G M Kroese, R P Pollard, S Ihrler, B van der Veet, A Vissink, H Bootsma, F K L Spijkervet